Background Levels of serum thyroid-stimulating hormone (TSH) indicate thyroid function, because thyroid hormone negatively controls TSH release. Genetic variants in the vascular endothelial growth factor A (VEGFA) gene are associated with TSH levels. The aim of this study was to characterise the association of VEGFA variants with TSH in a Danish cohort and to identify and characterise functional variants. Methods We performed an association study of the VEGFA locus for circulating TSH levels in 8445 Danish individuals. Lead variants were tested for allele-specific effects in vitro using luciferase reporter and gel-shift assays.
INTRODUCTION
The thyroid gland is an essential regulator of whole body energy expenditure and metabolic rate. Circulating levels and activities of thyroid hormones, their activating enzymes (deiodinases) and the regulating hormones thyrotropin/thyroidstimulating hormone (TSH) and thyrotropin-releasing hormone (TRH) are precisely balanced to ensure the euthyroid state. Circulating levels of TSH comprise a clinically valuable indicator of thyroid function, and in the absence of pituitary or hypothalamic failure, an increased level of TSH is a very sensitive marker of decreased thyroid function. Clinical reference levels for TSH define elevated TSH levels >4 mIU/L as being associated with clinically decreased thyroid function. 1 However, there is a marked interindividual, while low intraindividual variability in circulating TSH levels, as well as in the hypothalamic-pitutary-thyroid axis, 2 which appears to be highly heritable as evidenced by heritability estimates of 65% derived from twin studies. [3] [4] [5] Subclinical hypothyroidism (TSH >4 mIU/L with T4 levels within the reference range) is associated with an impaired metabolic phenotype, cardiovascular risk factors, elevated blood total cholesterol and blood pressure increase, decreased glomerular filtration rate and bone fractures. 6 However, association between TSH within the reference range and obesity is not well established. A meta-analysis encompassing 29 studies found 18 of these to report a positive association. 7 There have been reports of positive correlations between TSH levels and body mass index (BMI) in obese or overweight individuals, suggesting decreased thyroid function in these subjects, [8] [9] [10] but cross-sectional populationbased reports have also been made for the association between increased TSH levels and BMI. [11] [12] [13] Recent genome-wide association studies (GWAS) for circulating serum TSH levels have focused on common variants (minor allele frequency (MAF) >5%) and have identified at least 26 genomic loci to date, [14] [15] [16] [17] of which one was the vascular endothelial growth factor A gene (VEGFA) ( figure 1A ). Both the VEGF protein and its receptor, kinase insert domain receptor, are highly expressed in the thyroid gland. 18 In vivo, TSH administration increases VEGF release from the thyroid gland 19 and treatment of isolated, cultured thyrocytes with TSH also stimulates VEGF release. 20 Variants regulating the activity of the VEGFA locus are likely contributors to the observed TSH association, 14 because TSH levels indicate thyroid function. In order to investigate the molecular and genetic mechanisms in the VEGFA locus controlling circulating levels of TSH, we performed an association study using densely spaced SNPs of the VEGFA genomic region in three population-based cohorts from Denmark comprising 8445 individuals and meta-analysed them. The lead variants were further investigated to identify allele-specific effects using in vitro cell-based assays to elucidate the molecular mechanism supporting the observed clinical findings.
METHODS

Genetic association analysis Study participants
The study was conducted in accordance with the Declaration of Helsinki and approved by the Danish Data Protection Board and by the Ethical Committee of Copenhagen County. Informed written consent was obtained from all subjects before participation. The genetic association analyses were performed in three Danish study cohorts (Inter99, Health2006 and Health2008) that have been described previously elsewhere: 21 (1) Inter99 (ClinicalTrials.gov ID-no: NCT00289237) is a population-based study for ischaemic heart disease; 22 (2) Health2006 (Ethical Committee approval number: KA20060011) is a population-based study comprising individuals aged between 18 and 69 years from the South Western part of greater Copenhagen area. 23 This study was designed to address chronic health issues; (3) Health2008 (Ethical Committee approval number: KA20060011) is a cross-sectional population-based study. 24 
Biochemical and anthropometric measurements
The biochemical and anthropometric information on and phenotypical characterisation of study participants is described in online supplementary tables S1, S2 and S7 and has been presented previously. [22] [23] [24] Genotyping, variant calling and quality checks DNA extraction, genotyping and genotype call processing has been described previously. 21 25 A total of 8445 individuals (n Inter99 : 5420, n Health2006 : 2442, n Health2008 : 583) with Figure 1 (A) Schematic representation of SNPs in the vascular endothelial growth factor A (VEGFA) gene associated with circulating thyroid-stimulating hormone (TSH), serum VEGF, type 2 diabetes or insulin resistance. Chromosomal bp annotations are given for the hg19 assembly. The citations for the articles are: Porcu et al, 14 Debbette et al, 44 Choi et al, 43 Burgdorf et al 45 and Bonnefond et al. 46 DM, diabetes mellitus. (B) Genomic region surrounding the VEGFA gene. Simplified representations of ENCODE subtracks from Genome Browser are shown. TSS: transcription start site, PROM: promoter, H3K27AC: histone 3, lysine 27 acetylation (a mark of active and regulatory genomic DNA), H3K4Me1: histone 3, lysine 4 monomethylation (a mark of active enhancers), conservation: 24 placental mammals, ChIA-PET, chromatin interaction analysis paired-end tags (ChIA-PET) from ENCODE/Genome Institute of Singapore-Ruan, 47 48 c/EBP-β binding, chromatin-immunoprecipitation using antibody directed against ccaat enhancer binding protein β (c/EBPβ) followed by sequencing; DNase HS: DNase hypersensitivity. Genome Browser screenshots of the area are shown in online supplementary figure 21 25 ) post quality control.
SNP selection
SNPs from the VEGFA gene region (6:43737946-6:43754224 GRCh37) and within the adjoining flanking region (±75 kb) were selected covering a total of 166.2 kb (6:43662946-6:43829224 GRCh37) region. After removing SNPs with a MAF<0.005, a total of 15 non-coding SNPs were available from the VEGFA gene region for this study. Based on this SNP selection, a Bonferroni corrected p value corresponding 0.0033 was set as the significance threshold for SNP-TSH association testing.
SNP-TSH association testing and meta-analyses
The association testing between the SNPs and the serum TSH levels was performed individually for each cohort using the additive linear regression model adjusting for gender, age and first five principal components as covariates. The fasting circulating measures of TSH were transformed to natural log scale before the association testing to control for non-normalised data. Prior to the association testing, individuals with known thyroid pathologies and those with out-of-range TSH values (<0.4 mIU/L and >4.0 mIU/L) were removed. The method used for meta-analyses has been described previously. 21 
SNP metabolic traits association
Associations between an SNP and metabolic traits were tested among normal glucose-tolerant individuals from the Inter99 cohort using the general linear model assuming an additive genetic effect for the SNP. Association was tested with baseline measures and changes during follow-up (Δ values: follow up-baseline measurements) and was adjusted for gender and age. A p value of p<0.05 was considered to be significant for the follow-up and single SNP-metabolic trait testing. All association analyses were performed using PLINK V.1.07 (http://pngu.mgh.harvard.edu/ purcell/plink/) and R V.3.1.1 (http://www.r-project.org/).
LD estimations
LD estimation and proxy search was performed using 1000 genomes project data and an LD heat-map depicting pairwise r 2 values is available in online supplementary figure S1. Nongenotyped SNPs in LD with TSH-associated SNPs were retrieved from the Ensembl genome browser and SNPs with LD≥0.8 were inspected for evidence of differential allele effects using Genome Browser (https://genome.ucsc.edu/) (see online supplementary table S3).
In vitro molecular biology studies Reporter gene analysis
The VEGFA proximal promoter (hg19, chr6:43737097-43738057), corresponding to 849 bp of promoter and 252 bp of the first intron, was cloned into pGL4.10. Genomic regions containing rs881858 and rs9472138 were amplified by PCR from homozygous carriers and cloned into VEGFA pro/GL4.10 downstream of the luc gene to generate rs88 A/GL4.10, rs88 G/GL4.10, rs94 C/GL4.10 and rs94T/GL4.10. All constructs were confirmed by sequencing. Plasmid DNA was prepared using Qiagen Maxi Prep kit (Qiagen, Copenhagen Ø, Denmark) and ethanol precipitation method. Transfections were made in human embryonic kidney cells (HEK)293 cells (American Tissue Type Culture Collection, Rockville, Maryland, USA) using polyethylene imine (PEI25). Cells were harvested after 24 hours for luciferase assays (Dual Light, ThermoFisher Scientific, Copenhagen Ø, Denmark). Expression vectors for ccaat enhancer binding protein β (c/EBPβ) and C/EBP homology protein (CHOP)10 were a gift from Peter Johnson (Addgene plasmid #12557) and David Ron (Addgene plasmid #21899), respectively.
Electrophoretic mobility shift assay
Nuclear extracts from HEK293 cells were prepared as described previously. 26 Some extracts were prepared following incubation of cells with 1 mM dithiothreitol for 16 hours to induce CHOP10 via the unfolded protein response (UPR). 27 Complementary oligos representing the SNPs rs881858 were annealed and labelled with α-32 P-dATP (3000 Ci/mmol) by Klenow fill-in and purified using NICK columns (GE Healthcare, Brøndby, Denmark). Binding reactions were made as described previously, 26 separated with non-denaturing polyacrylamide gel-electrophoresis and visualised on Phosphorimager screen. Screens were scanned using a Molecular Dynamics Storm Scanner and the protein/DNA complexes analysed using ImageQuant Software V.3.5. Oligonucleotides used for cloning and electrophoretic mobility shift assays (EMSA) are listed in online supplementary table S3.
Statistics for molecular biology experiments
Results are expressed as mean±SEM. Statistical analysis was performed in GraphPad Prism software. Effects of SNP constructs were tested using analysis of variance with post hoc t-test and Bonferroni correction. Differences between treatments were considered significant at a p value <0.05 (two-tailed).
RESULTS
VEGFA and TSH association analyses
We investigated three population-based Danish cohort studies for association analyses of the VEGFA locus with circulating TSH: Inter99, Health2006 and Health2008 23 24 (see online supplementary table S1). We searched for genotyped SNPs located up to 75 kb upstream and downstream of the VEGFA transcription start site (VEGFA: Chr6:43737946-43754224). This region was defined based on the localisation of chromatin marks within this region (chromatin interaction analysis by paired-end sequencing (ChIA-PET)) indicating interaction with the VEGFA gene and localisation of nearby transcripts MRPS18A (upstream of VEGFA) and Loc100132354 and C6orf223 downstream of VEGFA) and we identified 15 SNPs in this region (see table 1 and online supplementary table S4) .
Four VEGFA region SNPs (rs9472138, rs881858, rs943080 and rs4711751) associated with fasting serum TSH levels at a study-wide significance level ( p combined <0.0033) (see table 1, figure 1A and online supplementary figure S2) in up to 8445 individuals following combined meta-analysis of the three cohorts. All four SNPs were in LD with each other (r 2 >0.4), and one SNP was a known signal (VEGFA rs9472138) 14 for circulating TSH. All the significantly associated SNPs were common (MAF>0.05).
Genomic marks qualifying VEGFA SNPs for further investigation
Common SNPs in high LD (r 2 >0.8) ( proxy SNPs) with the four significant SNPs in VEGFA: rs9472138, rs881858, rs943080 and rs4711751 was obtained from the Ensembl browser yielding 12 common SNPs linked with rs9472138 and rs881858 and 3 SNPs with rs943080 and rs4711751 (see online supplementary table S5 and figure S1), previously genotyped in the 1000 genomes project. These SNPs were considered functional candidates to explain the observed genetic association, because they are common and in high LD with the lead SNPs. Using ENCODE data tracks on Genome Browser (GRCh37/ hg19), 28 these SNPs were evaluated based on the presence of open chromatin structure (DNase-seq), conservation, marks of H3K27Ac (histone 3, lysine 27 acetylation) and H3K4Me1 (histone 3, lysine 4 monomethylation) and indication of protein binding to the SNP region by Chromatin-Immuno Precipitation (ChIP)-seq. Furthermore, it was also assessed if the SNP altered the binding site for factors shown to bind the region by ChIP (online supplementary table S5 and figure 1B). From this, it was evident that rs881858 was highly conserved with G being the ancestral allele. Furthermore, rs881858 was located in a region showing marks characteristic of active regulatory elements (H3K27Ac and H3K4Me1 and displaying evidence of close three-dimensional proximity to the VEGFA promoter (ChIA-PET). The region was also DNase hypersensitive suggesting an open chromatin structure (figure 1B).
Moreover, rs881858 was directly located in a site bound by the transcription factor c/EBPβ (encoded by CEBPB) (by ChIP-seq) in multiple cell lines, and predicted to be bound by CHOP. Thus, for rs881858 there is strong evidence of an allele-specific regulatory role. Performing the same analysis for the other SNPs did not reveal equal evidence of regulatory activity, conservation or protein binding to their vicinity (see online supplementary table S5 and figure S3 ). The rs881858 is located at the 3 0 end of the c/EBPβ binding site in a position that does not confer specificity to the c/EBPβ binding according to the position weight matrix for c/EBPβ (figure 1C), 29 whereas the binding site for CHOP is predicted to prefer the A-allele of the rs881858 compared with the G-allele. Thus, based on Ensembl and ENCODE data and differential predicted binding affinities to c/EBPβ and CHOP, the A-allele and G-allele of rs881858 could confer differential responses.
Association of G-allele of VEGFA rs881858 with decreased circulating TSH, increased thyroid hormone levels and metabolic traits
The effect size of rs881858 on circulating TSH levels was −0.092 ( p=2.2×10 −11 ) for the G-allele corresponding to an additive 2.3% decrease in TSH level per allele. Furthermore, free T4 levels were correspondingly increased in GG subjects compared with AA or AG subjects (GG: 15.4 (14.2-16.6) vs AA: 15.0 (13.8-16.3) pmol/L, p=0.0014), indicating a slightly increased thyroid function in GG individuals and an altered set point for the TSH/T4 axis (table 2). There was no available information on circulating levels of total T3 or thyroid hormone binding globulin for these subjects.
Since increased circulating TSH levels are associated with an impaired metabolic phenotype, it was tested if rs881858 associated with measures of glucose tolerance. The GG genotype of rs881858 was associated with slightly increased fasting and 2-hour post-OGTT plasma glucose levels (p=0.016 and 6.1×10 −3 ) (table 2) and increased HOMA-IR values (p=0.041) among glucose-tolerant subjects. BMI, haemoglobin A1c (HbA1c) and circulating leptin levels were not associated with carrier status of the rs881858. Moreover, we investigated measures of insulin release derived from OGTT data in relation to rs881858, but the insulinogenic index and the disposition index were not different between genotypes (table 2) .
Association of G-allele of VEGFA rs881858 with fasting circulating TSH, thyroid hormone levels and metabolic traits after 5-year follow-up
We studied changes in metabolic traits over the 5-year follow-up period among glucose-tolerant individuals from the Inter99 cohort (see online supplementary tables S2 and S6). Glucose (HbA1c: 0.66% and fasting plasma glucose: 0.86%) and insulin measures (fasting serum insulin: 3.2%; HOMA-IR: 4.1%) improved over a mean follow-up time of 5.4 years (see online supplementary table S2). However, none of these measures was associated with the VEGFA rs881858 polymorphism. Moreover, changes in BMI, circulating TSH and T4 levels were also not associated with VEGFA rs881858 (see online supplementary table S6). This indicates that the variant could act by modulating a given set point for TSH, since the phenotype of carriers appears to be stable during follow-up.
Reporter-gene analysis of VEGFA rs881858 and rs9472138 alleles
To determine if the most significant TSH-associated VEGFA SNP rs881858 or rs9472138 could confer functional changes to the VEGFA promoter activity, luciferase reporter vectors representing the SNPs were tested by transfection in HEK293 cells followed by luciferase assays (figure 2). Basal activity of the VEGFA minimal promoter was very high in HEK293 cells (not shown). The activity of the rs881858 A-allele was significantly higher than the G-allele (p=0.0012) (figure 2A), while there was no difference between the C-allele and the T-allele of VEGFA rs9472138.
The A-allele of VEGFA rs881858 is predicted to create a novel binding site for the transcription factor CHOP. To test the , heterozygosity at meta-analyses level; P HET , p value for heterozygosity; TSH, thyroid-stimulating hormone; VEGFA, vascular endothelial growth factor A.
Functional genomics
response of this site to CHOP, HEK293 cells were transfected with increasing amounts of CHOP expression vector in the presence of either rs881858 A-allele or G-allele reporter vector (figure 2B). With no CHOP overexpression, the VEGFA A-allele had increased activity compared with the G-allele (as in figure 2A ). Low amounts of CHOP expression vector increased the G-allele reporter activity, while there was no difference in the activity of the A-allele. Furthermore, increasing amounts of CHOP activity resulted in significantly decreased activity of the A-allele, indicating that the activity of this site is repressed by CHOP. Thus, the main action of CHOP on the predicted binding site created by rs881858 A-allele was to decrease reporter gene activity, which is in line with CHOP being a transcriptional repressor. 30 When overexpressing c/EBPβ, both the VEGFA A-allele and the G-allele of rs881858 responded by increasing luciferase activities by 25% ( p<0.05) at low levels of c/EBPβ, while decreasing at higher amounts of c/EBPβ (figure 2C). Since the rs881858 is not located in the core binding site of c/EBPβ (figure 1B), this is compatible with an equal response to c/EBPβ by either SNP allele.
The interaction between different amounts of c/EBPβ and CHOP was tested by co-transfection experiments in which varying ratios of c/EBPβ and CHOP were used with reporter vectors. For all combinations of CHOP in the presence of c/EBPβ, CHOP repressed the A-allele luciferase activity, while having no effect on the G-allele ( figure 2D) . Thus, based on reporter-gene assays, the A-allele of VEGFA rs881858 creates a novel response element of CHOP effectively repressing the minimal promoter activity of VEGFA, while this has no effect on the response to c/EBPβ. Furthermore, the A-allele confers higher reporter-gene activity in the basal state compared with the G-allele. figure 3B , lane 5 vs 6 and 9 vs 10). One complex was specific for A and G oligos as these efficiently outcompete the radio-labelled probes ( figure 3A , B, arrow), whereas competition using oligos containing known CHOP or c/EBPβ sites did not remove the complex (figure 3A, lane 1 vs 2, 5 vs 6, 5 vs 9 and figure 3B, lane 1 vs 2). Thus, both A and G versions of rs881858 can bind CHOP and c/EBPβ in vitro.
Binding affinities of VEGFA rs881858 (A/G) alleles
We also compared A and G oligos with oligos representing known CHOP or c/EBPβ binding sites 30 31 ( figure 3B ). CHOP and c/EBPβ oligos form complexes with the same mobility shift as A and G oligos. The same lower complex formed with either the CHOP or c/EBPβ probe, consistent with CHOP and c/EBPβ forming heterodimers. UPR induction increased c/EBPβ, A and G complex quantity ( figure 3B ). Furthermore, excess unlabelled CHOP oligo efficiently removed the VEGFA A and G probe binding at the lower complex, but not the top complex (arrow, figure 3B ). The A oligo consistently formed more lower complex than the G oligo, indicating increased binding strength of this probe. The top complex, specific for the rs881858 site ( figure 3A, B, arrows) , suggests that additional proteins may bind the VEGFA rs881858 site.
The c/EBPβ probe formed a faint complex (lanes 3 and 7 figure 3B, lanes 1-3, figure 3C ), most likely c/EBPβ homodimer, because it was super-shifted with c/EBPβ antibody and competed with unlabelled c/EBPβ probe. The known CHOP binding site of the tribbles pseudokinase 3 (TRIB3) promoter was used as probe for EMSA ( figure 3C, lanes 4-10) . As expected, the formed complex contained CHOP, shown by efficient competition by unlabelled CHOP ds-oligo (lane 4, figure 3C ) and decreased complex formation with addition of CHOP antibody (lane 5, figure 3C ). However, since excess of A or G did not remove TRIB3 probe binding, this indicates that the investigated VEGFA binding site has lower affinity for CHOP than the TRIB3 site with no difference between the A-allele and the G-allele of the rs881858. In summary, the VEGFA rs881858 site forms a binding site for both CHOP and c/EBPβ, where the A-allele forms more CHOP complex compared with the G-allele, but where this site measured against a wellcharacterised CHOP binding site has lower affinity for CHOP. Public Expressed quantitative trait locus (eQTL) databases were searched in order to determine if baseline thyroid VEGFA mRNA levels correlated with the SNPs significantly associated with TSH. Data from the GTEX database 32 are shown in online supplementary figure S4 indicating that baseline thyroid VEGFA transcript levels do not depend on genotypes of the SNPs rs881858, rs9472138, rs943080 or rs4711751.
DISCUSSION AND CONCLUSIONS
We focused on the genetic and molecular characterisation of the VEGFA locus with the aim to identify the functional variant(s) explaining the association with circulating TSH levels. [14] [15] [16] [17] We performed a dense association mapping for VEGFA SNPs using data from 8445 Danish individuals, and identified 4 SNPs significantly associated with circulating TSH levels, all of which were located more than 50 kb 3 0 of the coding region. Among the top hits we identified VEGFA rs881858, in high LD to the VEGFA GWAS SNP rs9472138. 14 The carriers of VEGFA rs881858 G-allele had a 2.3% decrease in circulating TSH levels in an additive manner. Moreover, the identified SNP rs881858 provided functional evidence of allele-specific effects at a VEGFA regulatory region binding CHOP and c/EBPβ proteins, thus connecting cellular stress-activated pathways with VEGFA gene regulatory activity and thyroid function, because CHOP production is activated by several types of cellular stress, such as endoplasmic reticulum (ER) stress, nutrient deprivation or oxidative stress. 33 Thus, data here and elsewhere 14 support that common variation in the VEGFA locus is an important determinant of circulating TSH levels. For the VEGFA locus, the variants most highly associated with TSH, rs881858 and rs9472138 are located >50 kb 3 0 of the VEGFA coding region, and equally close to a long non-coding RNA (Loc100132354), the function of which is not characterised. However, chromosomal interaction analysis identified contact points between the rs881858 SNP region and the promoter of VEGFA indicating control of VEGFA gene activity ( figure 1A) .
VEGFA is important for angiogenesis, homeostatic responses and organ growth in multiple tissues or cell types (white adipose tissue, 34 35 islets of Langerhans 36 37 ), and has also been shown to control T4-T3 conversion in hypothalamic tanycytes and thereby the feedback control of thyroid hormones to TRH and TSH release. 38 39 VEGFA rs881858 is also a known GWAS locus for chronic kidney disease and kidney function, 40 suggesting a possibility that this SNP controls responses in multiple organs, also as VEGFA is expressed ubiquitously. Since T4 levels were correspondingly increased in G-allele carriers, whose TSH levels were decreased, rs881858 seem to act primarily on the thyroid gland.
The G-allele is associated with increased VEGFA response to TSH, an increased T4 release and presumably increased T3 conversion in the hypothalamus and therefore resulting in decreased TSH release as a hypothalamic-pituitary response. However, it is also a possibility that the action of rs881858 can be on both VEGFA expression in the thyroid gland as well as on the hypothalamic tanycytes. Consistent with CHOP being a repressor, 41 A-allele carriers have lower T4 and increased TSH: for A-carriers the induction of ER stress may result in an impaired response to stimulate thyroid growth via VEGFA due to increased CHOP binding (figure 4). Since thyroid VEGF is increased by TSH, 19 this is consistent with rs881858 being more important in thyroid than in hypothalamus. Moreover, CHOP-deficient mice have increased angiogenesis, showing that CHOP normally acts to limit angiogenesis. 42 Interestingly, the genomic region containing rs881858 and rs9472138 is only modestly associated with levels of circulating VEGF, while regions situated both 5 0 of the VEGFA coding regions and further 3 0 in the C6orf223 locus are highly associated with circulating VEGF levels. 43 44 There is little or no LD between these regions and the LD block harbouring the SNPs associated with circulating TSH in the current study (rs881858, rs94772138, rs943080 and rs4711751) and these signals appear to be independent. Thus, it is conceivable that several regions in or near the VEGFA locus control different aspects of VEGF regulation and release. It seems reasonable that regulatory mechanisms operating in thyroid tissue to govern stress-induced VEGF production could differ from the molecular mechanisms contributing to the regulation of circulating VEGF levels. Although we do not know the contribution of the thyroid gland to the serum vascular endothelial growth factor (sVEGF) pool, it is likely to be only a minor contributor compared with VEGF produced by endothelial cells.
Although we present evidence for differential effects of alleles of VEGFA rs881858 by both reporter assays and direct binding, and have retrieved and inspected SNPs with high LD to this allele, we have not performed an extensive investigation of all linked SNPs in the VEGFA region for evidence of regulatory activity, and thus cannot exclude that additional functional SNPs may exist. Another limitation of our study is that we have no available data to show association between rs881858 alleles and levels of VEGFA mRNA transcript, protein levels or TSH-stimulated VEGF release. Data from public eQTL databases show no association between the investigated SNPs and thyroid VEGFA mRNA levels (see online supplementary figure S4) .
When examining the association of metabolic traits with VEGFA rs881858, GG homozygous subjects were slightly more insulin resistant, while having similar measures of obesity and similar insulin secretion capacity (table 2) . Adipose tissuespecific knockout of Vegfa results in inability to expand the adipose tissue, when demands for fat storage increases, exemplified by high-fat feeding. 34 Our results indicate that in the human setting the A-allele of VEGFA rs881858 via CHOP binding generates lower reporter-gene activity suggesting a Comp., competition using unlabelled ds-oligo; Ab., antibody used for super-shift of complexes; N.E., nuclear extract; CHOP, ds-oligo having the CHOP binding site from the tribbles pseudokinase 3 gene; 31 CEBP, ds-oligo having the c/EBPβ binding site from the c/EBPα gene promoter. 30 Labels to the left of images indicate formed complexes: c/EBPβ homodimer, CHOP/c/EBPβ heterodimer and arrows indicate rs881858 specific complexes not binding CHOP or c/EBPβ; n.s., non-specific. Shown are representative blots (n=2-4 of each).
decreased VEGFA response to cellular stress. This would result in an impaired angiogenic response of the A-allele, which is consistent with increased TSH levels. However, this is seemingly at odds with the GG-homozygous subjects being more insulin resistant, because in mouse models insulin resistance is observed when the angiogenic response and therefore adipogenesis is impaired. 34 35 Thus, further studies are necessary to determine the tissue-specific effects of VEGFA and genetic variation on different human tissues. The VEGFA SNP rs9472138 has previously been associated with visceral obesity and insulin resistance in women, 45 further underlining the importance of genetic variation in VEGFA also for human adipose tissue expansion. Of note, increased circulating TSH is associated with obesity and impaired cardiometabolic health, which could indirectly affect the observed associations between insulin resistance and VEGFA rs881858. Mendelian randomisation studies in large populationbased cohort could potentially resolve this. Figure 4 A model illustrating the possible involvement of vascular endothelial growth factor A (VEGFA) rs881858 in regulating thyroid function and the set point of thyroid-stimulating hormone (TSH). The rs881858 A-allele is repressed by C/EBP homology protein (CHOP), which is activated by the cellular stress, resulting in less VEGFA enhancer activity, with predicted less thyrocyte VEGF produced. The result is predicted to be reduced angiogenesis and less thyroid compensatory expansion. This will result in less T4 production, less feedback inhibition of thyrotropin-releasing hormone and TSH release and therefore increased circulating TSH levels. A higher TSH level will result in increased stimulation of the TSH receptor and a higher degree of activation of the endoplasmic reticulum stress response. Dashed lines illustrate rs881858 A-allele-related effects.
